Wechselwirkungen · Reyataz
REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 50
HOS-112180 · Präparat HOS-093615
If genotyping is not feasible, full monitoring of safety and efficacy should be performed. Fluconazole 200 mg once Atazanavir and fluconazole concentrations No dosage adjustments are daily were not significantly modified when needed for fluconazole and (atazanavir 300 mg and REYATAZ/ritonavir was co-administered REYATAZ. ritonavir 100 mg once daily) with fluconazole. ANTIMYCOBACTERIAL Rifabutin 150 mg twice Rifabutin AUC: ↑48% (↑19% ↑84%)** When given with REYATAZ, weekly Rifabutin Cmax: ↑149% (↑103% ↑206%)** the recommended dose of (atazanavir 300 mg and Rifabutin Cmin: ↑40% (↑5% ↑87%)** rifabutin is 150 mg 3 times per ritonavir 100 mg once daily) week on set days (for example 25-O-desacetyl-rifabutin AUC: ↑990% Monday-Wednesday-Friday). (↑714% ↑1 361%)** Increased monitoring for 25-O-desacetyl-rifabutin Cmax: ↑677% rifabutin-associated adverse (↑513% ↑883%)** reactions including neutropenia 25-O-desacetyl-rifabutin Cmin: ↑1 045% and uveitis is warranted due to (↑715% ↑1 510%)** an expected increase in exposure to rifabutin. Further **When compared to rifabutin 150 mg dosage reduction of rifabutin to once daily alone. Total rifabutin and 150 mg twice weekly on set 25-O-desacetyl-rifabutin AUC: ↑119% days is recommended for (↑78% ↑169%). patients in whom the 150 mg dose 3 times per week is not In previous studies, the pharmacokinetics tolerated. It should be kept in of atazanavir was not altered by rifabutin. mind that the twice weekly dosage of 150 mg may not provide an optimal exposure to rifabutin thus leading to a risk of rifamycin resistance and a treatment failure. No dose adjustment is needed for REYATAZ.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifabutin (HOS-086262) fluconazole (HOS-087945) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T13:00:00Z · SHA-256 ff5481974bd7c752b73fa0c147cf3e96fc892edc735359fa71817833db471beb · Passage 8636d5f40f2d59b4431c4b6441a822c9757fee6002c3bac44d10a6c85c5838ba · Zeichen 27032–30282 im Abschnitt